Form 4: Mirum Pharmaceuticals SVP, Global Controller Howe Jolanda Reports Stock Transactions

Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities, including transactions to cover tax obligations and those executed under a Rule 10b5-1 plan.

Summary

• On March 15, 2025, Jolanda Howe acquired 5,315 shares of common stock through the vesting of performance restricted stock units and disposed of the same amount.
• On March 17, 2025, Howe sold 2,900 shares at $44.2143 per share to cover tax withholding obligations.
• Also on March 17, 2025, Howe acquired 52,900 shares through the exercise of a stock option at $2.94 and sold 50,111 shares at a weighted average price of $44.3341, 2,789 shares at $44.7481, and 1,806 shares at $44.3592.
• Following these transactions, Howe directly owns 9,436 shares of common stock and 2,658 performance restricted stock units, as well as no stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the trading activities of key personnel.

Stakeholder Impact

• Shareholders are informed about insider trading activities, which can influence investor confidence.

Key Dates